Table.1 Baseline characteristics of 67 patients who underwent surgical resection
From: Outcomes of adjunctive surgery for nontuberculous mycobacterial pulmonary disease
Characteristics | n = 67 |
|---|---|
Age years, median (IQR) | 57 (50, 65) |
Female sex, n (%) | 53 (79.1) |
BMI kg/m2 (n = 47), median (IQR) | 20.1 (18.7, 21.3) |
Smoking status, Never/former, n (%) | 59 (88.1)/8 (11.9) |
Underlying disease | |
 History of pulmonary TB, n (%) | 10 (14.9) |
 Lung cancer, n (%) | 2 (3) |
 Asthma, n (%) | 2 (3) |
 COPD, n (%) | 1 (1.5) |
 Other malignancy, n (%) | 5 (7.5) |
 Diabetes mellitus, n (%) | 3 (4.5) |
 Charlson comorbidity index, median (IQR) | 2 (1, 3) |
Causative Mycobacterium species | |
 MAC, n (%) | 39 (58.2) |
  M. avium, n (%) | 18 (26.9) |
 M. intracellulare, n (%) | 21 (31.3) |
 MABC, n (%) | 24 (35.8) |
  M. abscessus, n (%) | 16 (23.9) |
  M. massiliense, n (%) | 8 (11.9) |
 M. kansasii, n (%) | 3 (4.5) |
 M. fortuitum, n (%) | 1 (1.5) |
Clarithromycin resistance in MABC | |
  M. abscessus (n = 13), S/IR or R, n (%) | 2 (3)/11 (16.4) |
  M. massiliense (n = 8), S/IR or R, n (%) | 7 (87.5)/1 (12.5) |
Preoperative positive NTM culture, n (%) | 54 (80.6) |
CT pattern | |
 Non-cavitary nodular bronchiectatic, n (%) | 19 (28.4) |
 Cavitary nodular bronchiectatic, n (%) | 34 (50.7) |
 Fibrocavitary, n (%) | 14 (20.9) |
Disease extent | |
 Involving a single lobe, n (%) | 7 (10.4) |
 Involving more than three lobes, n (%) | 46 (68.7) |
 Bilateral involvement, n (%) | 49 (73.1) |
 Involving all lobes, n (%) | 12 (17.9) |
Preoperative PFT | |
 FEV1/FVC ratio, median (IQR) | 76.5 (70, 80.8) |
 % predicted FEV1, median (IQR) | 94 (83.3, 101.8) |
 % predicted FVC, median (IQR) | 90 (81, 99) |
 % DLCO, median (IQR) | 87 (77, 96.5) |
Preoperative NTM treatment | |
 On antibiotics treatment prior to surgery, n (%) | 61 (91) |
  Guideline-adhering regimens, n (%) | 58 (95.1) |
  Macrolide-based regimen with intravenous drugs, n (%) | 29 (47.5) |
  Macrolide-based regimen without intravenous drugs, n (%) | 31 (50.8) |
  Non-macrolide-based regimen, n (%) | 1 (1.6) |
 Treatment duration, months, median (IQR) | 14 (9, 25) |
 No antibiotic treatment before surgery, n (%) | 6 (9) |
Surgical indication | Â |
 Persistent NTM culture positivity, n (%) | 54 (80.6) |
 Radiographic aggravation and/or persistent cavity, n (%) | 7 (10.4) |
 Massive hemoptysis, n (%) | 3 (4.5) |
 Initiation of therapy, n (%) | 1 (1.5) |
 Others, n (%) | 2 (3) |